Clinical Trials Directory

Trials / Completed

CompletedNCT01537393

Cornea Preservation Time Study

Effect of Corneal Preservation Time on Long-Term Graft Success

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
1,174 (actual)
Sponsor
Case Western Reserve University · Academic / Other
Sex
All
Age
30 Years – 90 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine if the 3-year graft failure rate following endothelial keratoplasty performed with donor corneas with a preservation time of 8 to 14 days is non-inferior to the failure rate when donor corneas with a preservation time of 7 or fewer days are used.

Detailed description

When the donor cornea is removed from the person who died, it is prepared for transplantation by an eye bank. The donor cornea is placed into a liquid that helps preserve the cornea until it is transplanted. The Food and Drug Administration (FDA) has approved storage of the cornea in this liquid for up to 14 days before the transplant. The purpose of this study is to see if the length of time the donor cornea is kept in the preservation liquid before the transplant affects the likelihood of the transplant being successful. We will follow participants for 3 years after transplant to see if there are any differences in transplant success or in the number of transplanted endothelial cells (the layer of cells that line the undersurface of the cornea) on the corneas that were preserved for 7 days or less compared to those preserved between 8 and 14 days. We have no reason to believe that there is any greater risk for transplant failure with either preservation time group.

Conditions

Interventions

TypeNameDescription
BIOLOGICALCornea tissue transplantCornea tissue preserved 0 to 7 days
BIOLOGICALCornea tissue transplantCornea tissue preserved 8 to 14 days.

Timeline

Start date
2012-04-16
Primary completion
2017-06-30
Completion
2017-06-30
First posted
2012-02-23
Last updated
2018-04-23
Results posted
2018-04-23

Locations

40 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01537393. Inclusion in this directory is not an endorsement.